SALSA MLPA P520 MPN mix 2 probemix

application: Myeloproliferative neoplasms
region: JAK2, MPL, CALR and KIT mutations
[login for my products]
version: A2
sold since: 2017-09-18

item no. description price
P520-025R SALSA MLPA P520 MPN mix 2 probemix – 25 rxn € 237
P520-050R SALSA MLPA P520 MPN mix 2 probemix – 50 rxn € 474
P520-100R SALSA MLPA P520 MPN mix 2 probemix – 100 rxn € 948
EK1-FAM SALSA MLPA EK1 reagent kit – 100 rxn - FAM € 294
EK1-Cy5 SALSA MLPA EK1 reagent kit – 100 rxn - Cy5 € 294
EK5-FAM SALSA MLPA EK5 reagent kit – 500 rxn - FAM € 1355
EK5-Cy5 SALSA MLPA EK5 reagent kit – 500 rxn - Cy5 € 1355

Please note that both a probemix and reagent kit are needed to perform MLPA.

description
The P520-A2 MPN mix 2 is an MLPA probemix that allows higher detection sensitivity for mutations. Only 1% allele burden is required for detection of the eight different mutations frequently found in MPN samples.

With each P520 probemix order, an artificial DNA sample (SD057) mimicking 1% allele burden is supplied for data binning in the fragment analysis procedure, and as an artificial positive control for all the mutation-specific probes. This SD057 should be used in each P520 experiment for correct data binning and mutation calling.

This SALSA® MLPA® probemix is intended for research use only (RUO) purposes.

Note 1: The use of this product requires two modifications as compared to the General MLPA Protocol. First, the PCR reaction should be prolonged from 35 to 40 cycles. Second, we strongly recommend to use ≥100 ng of patient DNA per MLPA reaction (maximum 400 ng of DNA) for most optimal and robust mutation detection with the P520 probemix. Customers are strongly advised not to make any additional modifications to the MLPA protocol, as this could potentially lead to false positive or false negative results for the mutation calling.

Note 2: The optimal range for quantitative detection with P520 probemix is narrow, in between 1% and 5% allele burden. Outside of this narrow range, this assay is only qualitative. Probemix P420 MPN mix 1 (available upon request) can be used for patient samples with a >10% allele burden, which will generate a saturated mutation-specific signal when using P520.

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell malignancies, characterized by excessive production of blood cells. MPNs are subdivided in polycytemia vera (PV), essential thrombocytemia (ET), primary myelofibrosis (PMF) and less common conditions like chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), hypereosinophilic syndrome (HES) and mastocytosis.

Discovery of a frequent JAK2 mutation (9p24.1), common to classic MPNs (PV, ET and PMF), has linked these diseases on a molecular level. The current WHO diagnostic criteria for classic MPNs include presence of JAK2, CALR or MPL mutations. The JAK2 V617F point mutation is detected in ~98% of PV patients, and in ~60% of patients with ET and PMF, whereas other JAK2 exon 12 mutations are commonly found in V617F negative PV patients. P520-A2 MPN mix 2 contains three mutation-specific JAK2 probes: one probe for V617F and two probes for the most common exon 12 mutations N542_E543del and E543_D544del.

Mutations in the MPL gene (1p34.2) are found in 4-11% of JAK2 V617F negative ET and PMF patients. P520-A2 MPN mix 2 contains two mutation-specific probes for MPL, W515K and W515L, that are diagnostically relevant in PV, ET and PMF according to the WHO classification.

The discovery of novel CALR gene (19p13.13) mutations in ET and PMF provides additional diagnostic tools for MPNs. Patients with ET and PMF but negative for JAK2 and MPL mutations, have been reported to harbour somatic insertions and deletions in exon 9 of the CALR gene. A 52-bp deletion (type 1) and a 5-bp insertion (type 2) are the most common mutations found in the CALR gene (53% and 32%, respectively). These mutations result in a frameshift to an alternative reading frame (Klampfl T et al. 2013, N Engl J Med. 369:2379-90; Nangalia J et al. 2013, N Engl J Med. 369:2391-405). CALR mutation-specific probes for the 52-bp deletion (L367fs*46, type 1) and 5-bp insertion (K385fs*47, type 2) are included in this probemix.

In addition, a probe specific for the D816V mutation in the KIT gene (4q12) is present. This is the most common KIT mutation and is present in >90% of patients with systemic mastocytosis (SM). Consequently, the presence of this mutation is considered a diagnostic criterion of SM according to the WHO classification.

Finally, 17 reference probes are included in the P520-A2 probemix, detecting different autosomal chromosomal locations which are relatively stable in MPNs. Please note that the probe signals of the reference probes in this P520 probemix show much greater variation as compared to standard MLPA products. This is due to the nature of the high sensitivity of this assay.

This SALSA® MLPA® probemix is designed to detect the presence of the aforementioned mutations in a DNA sample. Note that a mutation or polymorphism in the sequence detected by a probe can also cause a reduction in relative peak height, even when not located exactly on the ligation site! In addition, some probe signals can be more sensitive to sample purity and small changes in experimental conditions.

This MLPA probemix cannot detect any mutations that are outside the target sequences of the MLPA probes. Neither can it be used for copy number detection of the aforementioned target genes. Even when MLPA analysis did not detect any aberrations, the possibility remains that changes in the corresponding gene(s) do exist but remain undetected. This probemix covers only the most frequent mutations of clinical and diagnostic relevance in MPNs. Rare or infrequent mutations are not covered. If mutation calling with MLPA is negative for a patient sample, we recommend to perform sequencing of the JAK2, MPL and CALR genes to detect the rare or unknown mutations possibly present in a patient sample.

related products
SALSA MLPA P420 MPN mix 1 probemix
This probemix is a conventional MLPA probemix allowing detection of the same mutations as included in P520 on samples with >10-20% allele burden (up to 100% allele burden).

product history
version A2: Several probes have been changed in lenght, but not in the sequence detected.
new products
P420-MPN mix 1
Myeloproliferative neoplasms
P475-FOXP1 - FOXP2
mental retardation
improved products
P241-MODY Mix 1
Maturity-Onset Diabetes of the Young (MODY)
P374-Microdeletion-8
Microdeletion follow-up: 7q11, PWS/AS, Miller-Dieker, Smith-Magenis, RETT
P077-BRCA2 Confirmation
Breast cancer, hereditary
P318-Hirschsprung-2
Hirschsprung disease
Newsletter  |  Home  |  Site map  |  Terms and Conditions  |  Search  |  Copyright © 2017 MRC-Holland